ADAR1 Capital Management LLC has strengthened its position in KALA BIO, Inc. with a notable 35.7% increase in shareholdings. The firm’s total stake now stands at nearly 299,000 shares valued at $1.7 million, reflecting heightened confidence in KALA BIO’s prospects.

ADAR1 Capital Management has significantly raised its stake in Contineum Therapeutics, increasing its shareholding by 105.2% in the first quarter. The purchase brings its total shares in the biotech company to 168,765, valued at approximately $1.18 million.

Braidwell LP has acquired 140,000 shares of Beta Bionics, Inc., worth approximately $1.7 million. An SEC filing confirms that the purchase gives Braidwell LP about 0.32% ownership of the company, indicating growing investor interest in biotech innovations.

Panagora Asset Management Inc. has invested in 149,908 shares of Protagonist Therapeutics, Inc. (PTGX) in the first quarter. The purchase, valued at approximately $7.25 million, underscores widening interest in the company among institutional investors.

A decade-long study by Harvard scientists suggests that lithium deficiency, triggered by amyloid plaques in the brain, may be a key factor in the early stages of Alzheimer’s disease. By testing innovative lithium compounds that evade plaque capture, researchers were able to reverse memory loss in mice at far lower doses than those used for psychiatric treatments.

Colossal Biosciences has introduced three genetically engineered dire wolves named Romulus, Remus, and Khaleesi. This milestone marks a significant first step in reviving a species thought lost to history, opening new possibilities for the future of de-extinction efforts.

The U.S. Food and Drug Administration has requested additional information from Telix Pharmaceuticals regarding its experimental diagnostic tool for a form of kidney cancer. This development underscores the regulatory rigor that emerging medical products must meet before approval.

ADMA Biologics, Inc. has caught the attention of investors intrigued by its optimistic valuation metrics and forward-looking prospects. A recent bullish thesis proposes that the stock’s financial ratios, along with expert commentary, could be key indicators of future growth.

UL Solutions has opened the first laboratory dedicated to testing commercial and service robots, a notable development in today’s high-tech economy. Located in Northbrook, Illinois, this facility marks an important milestone in robotics innovation.

Taikang Asset Management Hong Kong Co Ltd has purchased 2,858 shares in Axon Enterprise, Inc, valued at around $1,503,000, according to a recent SEC filing. This move highlights a growing trend of institutional interest in the biotechnology firm and reflects broader market engagement with Axon’s business potential.

Perseverance is uncovering strange, frozen waves in Mars’ sandy ripples that may shed light on how wind has shaped the Red Planet. Along the way, it has discovered helmet-shaped rocks, sparking new perspectives on Mars’ present condition and future possibilities for exploration.

Analysts at Wedbush project that Telix Pharmaceuticals could achieve an earnings per share of $0.89 by 2028. The research note, released on August 21st, underscores the potential growth trajectory for the pharmaceutical company in the coming years.

A Montana man has been sentenced to six months in prison for illegally cloning and breeding giant sheep. His operation spanned Texas and Minnesota, where hybrid sheep were used in captive trophy hunts.

Swiss National Bank recently reduced its holding in Rhythm Pharmaceuticals by a modest 900 shares during the first quarter, as disclosed in a new SEC filing. Despite the small adjustment, the bank retains a significant position in the company.

PNC Financial Services Group has quietly pared back its stake in Vericel Corporation. A recent SEC filing shows the bank sold 378 shares in the first quarter—an 8.2 percent trim that leaves it holding 4,251 shares of the NASDAQ-listed biotech firm.

Zacks Small Cap has inched its third-quarter 2025 earnings forecast for Longeveron Inc. higher, trimming the biotech’s expected loss to 26 cents a share. The research note, issued Aug. 14 by analyst B. Sorensen, offers a modest but notable vote of confidence in the Nasdaq-listed company.

William Blair has lowered its third-quarter 2025 earnings forecast for Jasper Therapeutics to a loss of $0.75 per share, according to an analyst note issued on August 14. The deeper-than-expected projection, reported by Defenseworld.net, signals mounting challenges for the California-based biotech firm.

A new study reveals that Naloxone, the life-saving drug used to treat opioid overdoses, binds more to opioid receptors in women’s brains than in men’s. This finding suggests that sex differences may affect the efficacy of overdose treatments.

NASA is set to revolutionize Mars exploration with the Skyfall mission, deploying six helicopters from a flying mothership to advance autonomous aerial exploration. This bold initiative aims to pave the way for humanity’s first footsteps on the Red Planet.

Skin allergies are common and often frustrating to diagnose. But new technology could soon help change that. Emerging advances, including artificial intelligence, promise a more efficient future in allergy testing.

In a leap forward for robotics, the Walker S2 humanoid robot can now swap its own battery in just three minutes, challenging the autonomy of Tesla’s Optimus. This advancement marks the transition of battery swap technology from electric vehicles to the realm of industrial robotics.